🏛️ Verified NIH Record • Updated 2026-07-06

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma (NCT04685616)

A Randomised Phase III Trial With a PET Response Adapted Design Comparing ABVD +/- ISRT With A2VD +/- ISRT in Patients With Previously Untreated Stage IA/IIA Hodgkin Lymphoma

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: University College, London

🩺 Plain-English Summary (8th-Grade Level)

RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand. Trial 2 will be led by the Canadian Cancer Trials Group (CCTG) and conducted in North America, with CCTG the regulatory sponsor in Canada, and University of Miami the regulatory sponsor and IND holder in the US. Datasets from Trial 1 and Trial 2 will be combined to achieve the total sample size. Data analysis will be performed by UCL and therefore UCL is responsible for the clinicaltrials.gov entry. Eligible patients will be randomised to receive either ABVD or A2VD chemotherapy. An interim PET-CT scan will be performed after 2 cycles of treatment, which will be used to adapt subsequent treatment. Patients will receive a total of 3-4 cycles of chemotherapy and may also receive involved site radiotherapy as consolidation. Patients will be followed up for a minimum of 5 years after treatment.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (13 items) and avoid the listed exclusions (18 items).

Location: Stanford University - (Stanford Cancer Institute) — Stanford, California

Age range: 16 Years to 69 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Previous treatment for Hodgkin lymphoma, excluding short courses of oral corticosteroids at a dose of 100mg prednisolone (or equivalent) for up to 7 days
  • Infradiaphragmatic disease
  • Nodular lymphocyte predominant Hodgkin lymphoma
  • Absence of FDG-avid lesions on baseline PET scan
  • Age 70 years or over or age 15 years or under
  • Other cancer diagnosed with the last 5 years. Patients with completely excised carcinoma in situ of any type and basal or squamous cell carcinoma of the skin are not excluded
  • Recurrent or persistent other cancer within last 5 years irrespective of date of initial diagnosis
  • Pre-existing grade ≥1 sensory or motor neuropathy from any cause
  • History of or current progressive multi-focal leukoencephalopathy or other chronic condition of the brain
  • Symptomatic neurologic disease compromising normal activities of daily living or requiring medications
  • Infection with HIV, hepatitis C or active hepatitis B infection (surface antigen or DNA positive)

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (72 Sites)

Showing the first 25 of 72 sites.

  • Stanford University - (Stanford Cancer Institute) — Stanford, California
  • University of Miami School of Medicine — Miami, Florida
  • Memorial Sloan Kettering Cancer Center — New York, New York
  • Royal North Shore Hospital — Saint Leonards, New South Wales
  • Townsville University Hospital — Townsville, Queensland
  • Royal Adelaide Hospital — Adelaide,
  • Box Hill Hospital — Box Hill,
  • Royal Brisbane and Women's Hospital — Brisbane,
  • Royal Darwin Hospital — Darwin,
  • Liverpool Hospital — Liverpool,
  • Sunshine Hospital (Western Health) — Melbourne,
  • Concord Repatriation General Hospital — Sydney,
  • St George Hospital — Sydney,
  • AZ Delta Campus Rumbeke — Roeselare, West Flanders
  • Universitair Ziekenhuis Antwerpen — Antwerp,
  • Ziekenhuis Netwerk Antwerpen — Antwerp,
  • UZ Leuven — Leuven,
  • CHU-UCL Namur — Namur,
  • QEII Health Sciences Centre — Halifax, Nova Scotia
  • Juravinski Cancer Centre — Hamilton, Ontario
  • Ottowa Hospital Research Institute — Ottawa,
  • Saint John Regional Hospital — Saint John,
  • University Health Network Princess Margaret Cancer Centre — Toronto,
  • Vancouver Cancer Centre — Vancouver,
  • CancerCare Manitoba — Winnipeg,

📞 Contact the Study Coordinator

Phone: +44(0)207 679 9860

Email: ctc.radar@ucl.ac.uk

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
  • 💵 Compensation indicated: Patients will receive a total of 3-4 cycles of chemotherapy and may also receive involved site radiotherapy as consolidation.

More studies in Hodgkin Lymphoma

Explore by condition: All Hodgkin Lymphoma clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗